Douglas A. Dachille - 22 Jun 2026 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Reporting relationship: Director
Issuer ticker: BBIO
Reported as of: 22 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Jun 2026, 18:05:23 UTC
Prior SEC filing: 21 May 2026
Next SEC filing: 06 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Will Solis, Attorney-in-Fact

Key filing fact

Douglas A. Dachille filed Form 4 for BridgeBio Pharma, Inc. (BBIO) on 24 Jun 2026.

Key facts

This page summarizes Douglas A. Dachille's Form 4 filing for BridgeBio Pharma, Inc. (BBIO).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 24 Jun 2026, 18:05.

Change

Previous filing in this sequence was filed on 21 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001652908 Primary reporting owner

Dachille Douglas A.

Relationship: Director
Address: C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO
Signature: /s/ Will Solis, Attorney-in-Fact
Signature date: 24 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBIO transaction

Common Stock

Award

Transaction value
Shares: +3,990
Change %: +61%
Price: $0.000000^*
Shares after: 10,579
Date: 22 Jun 2026
Ownership: Direct
Footnotes: F1, F2

BBIO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 20,000
Date: 22 Jun 2026
Ownership: By The Dachille 2012-1 Family Trust
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BBIO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +5,277
Change %
Price: $0.000000^*
Shares after: 5,277
Date: 22 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,277
Exercise price: $68.92
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

Footnote F2

Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Footnote F3

These shares are owned directly by The Dachille 2012-1 Family Trust for the benefit of the Reporting Person's children, for which the Reporting Person's spouse is the trustee. The Reporting Person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose.

Footnote F4

The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

SEC remarks

Exhibit 24 - Power of Attorney